12/8/2022 0 Comments Cad risk factors timi![]() ![]() Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 20: a systematic review and analysis. Keywordsįowkes FGR, Rudan D, Rudan I, et al. All patients with PAD should be considered for aggressive pharmacological management that is likely to positively impact their overall major adverse cardiovascular and limb events. ![]() Recently, SGLT2 inhibitors and GLP agonists also showed a reduction in the risk of adverse cardiovascular events in patients with atherosclerotic vascular disease and type 2 diabetes including the PAD patients. Lipid-lowering agents, statins and PCSK9 inhibitors, have been shown to reduce cardiovascular events in patients with PAD. Cilostazol reduced claudication and restenosis post-vascular intervention. Although ticagrelor and vorapaxar reduced major adverse cardiovascular and limb events in certain subgroups of PAD patients, this came at the expense of increase in bleeding. The use of antiplatelets in symptomatic patients with PAD is recommended, and clopidogrel is preferred over aspirin. In addition, using the risk score to categorize patients also effectively defines a gradient for benefit with specific treatments such as low-molecular-weight heparins, glycoprotein IIb/IIIa inhibitors, and an early invasive strategy.Pharmacologic preventative therapies in the peripheral arterial disease (PAD) patients improve long-term mortality and morbidity. The risk score has been validated in several other trials of UA/NSTEMI. ![]() The rate of death, MI, or urgent revascularization significantly increased as the TIMI risk score increased, ranging from 40% for patients with a risk score of 6 or 7. Each predictor carried similar prognostic weight therefore, a risk score was constructed as the simple arithmetic sum of the number of predictors. Using multivariable logistic regression, seven independent predictor variables were identified: age ≥65 years, ≥3 risk factors for coronary artery disease (CAD), known CAD (stenosis ≥50%), severe anginal symptoms (≥2 anginal events in preceding 24 h), use of aspirin in the last seven days, ST-segment deviation ≥0.05 mV, and elevated serum cardiac markers of necrosis. The Thrombolysis In Myocardial Infarction (TIMI) risk score for UA/NSTEMI is an integrated approach that uses baseline variables that are part of the routine medical evaluation to identify patients at high risk for death and other major cardiac ischemic events. ![]() Risk stratification in unstable angina (UA)/non–ST-segment elevation myocardial infarction (NSTEMI) can provide an estimate of a patient’s prognosis and optimize clinical choices. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |